ifosfamide and etoposide
Showing 1 - 25 of 1,033
Non-Hodgkin's Lymphoma Trial in New York (Etoposide, carboplatin, ifosfamide, Rituximab, Ifosfamide, Etoposide, Carboplatin,
Completed
- Non-Hodgkin's Lymphoma
- Etoposide, carboplatin, ifosfamide
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
May 23, 2022
DLBCL (DLBCL) Trial (Glofitamab, Obinutuzumab, Tocilizumab)
Recruiting
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Glofitamab
- +6 more
-
Pembroke Pines, Florida
- +3 more
Jan 23, 2023
Effect of Drug, Toxicity, Drug, Secondary Resistance Trial in Beijing (Apatinib Mesylate, ifosfamide and etoposide)
Completed
- Effect of Drug
- +2 more
- Apatinib Mesylate
- ifosfamide and etoposide
-
Beijing, Beijing, ChinaPeking University People's Hospital
Mar 12, 2022
Classic Hodgkin's Lymphoma Trial in Beijing (Sintilimab, Carboplatin, Etoposide)
Recruiting
- Classic Hodgkin's Lymphoma
- Sintilimab
- +4 more
-
Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Sep 12, 2022
Neuroblastoma, Pediatric Cancer Trial in New York (Cyclophosphamide, Topotecan, Vincristine)
Recruiting
- Neuroblastoma
- Pediatric Cancer
- Cyclophosphamide
- +7 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jan 11, 2023
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in United States (drug, other, biological)
Active, not recruiting
- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Carboplatin
- +4 more
-
Duarte, California
- +3 more
Oct 24, 2022
B-cell Non Hodgkin Lymphoma Trial (Odronextamab, Loncastuximab tesirine, Rituximab)
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- Odronextamab
- +8 more
- (no location specified)
Aug 7, 2023
Mantle-Cell Lymphoma Trial in Miami (G-CSF, Rituximab, Cyclophosphamide)
Active, not recruiting
- Mantle-Cell Lymphoma
- G-CSF
- +10 more
-
Miami, FloridaUniversity of Miami
Aug 12, 2021
Mature B-Cell Non-Hodgkin Lymphoma Trial (Obinutuzumab, Glofitamab, Rituximab)
Not yet recruiting
- Mature B-Cell Non-Hodgkin Lymphoma
- Obinutuzumab
- +6 more
- (no location specified)
Sep 6, 2022
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in Miami (Acalabrutinib,
Terminated
- Diffuse Large B Cell Lymphoma
- +3 more
- Acalabrutinib
- +4 more
-
Miami, FloridaUniversity of Miami
Aug 23, 2022
Lymphoma Trial in Houston (Radiation Therapy, Dexamethasone, Etoposide phosphate)
Recruiting
- Lymphoma
- Radiation Therapy
- +5 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Dec 9, 2022
Relapsed Diffuse Large B-cell Lymphoma, Refractory DLBCL Trial in Worldwide (Polatuzumab Vedotin, Mabthera, Ifosfamide)
Recruiting
- Relapsed Diffuse Large B-cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Polatuzumab Vedotin
- +4 more
-
Graz, Austria
- +62 more
Aug 2, 2022
Hodgkin Lymphoma Trial in Saint Petersburg, Irkutsk (Nivolumab, Ifosfamide, Carboplatin)
Recruiting
- Hodgkin Lymphoma
- Nivolumab
- +3 more
-
Saint Petersburg, Pesochny, Russian Federation
- +2 more
Jul 19, 2021
Diffuse Large B-cell-lymphoma Trial in Saint Louis, Cleveland (Venetoclax, Rituximab, Ifosfamide)
Active, not recruiting
- Diffuse Large B-cell-lymphoma
- Venetoclax
- +4 more
-
Saint Louis, Missouri
- +2 more
Nov 14, 2022
Peripheral T-cell Lymphoma Trial in Singapore (Selinexor, ICE Chemotherapy)
Completed
- Peripheral T-cell Lymphoma
- Selinexor
- ICE Chemotherapy
-
Singapore, SingaporeNational Cancer Centre Singapore
Apr 27, 2021
CD20 Positive, Recurrent DLBCL, Refractory DLBCL Trial in Buffalo (drug, other, biological)
Active, not recruiting
- CD20 Positive
- +6 more
- Carboplatin
- +6 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Oct 11, 2021
Diffuse Large B Cell Lymphoma Trial (Pembrolizumab, Rituximab, Ifosfamide)
Recruiting
- Diffuse Large B Cell Lymphoma
- Pembrolizumab
- +4 more
-
Headington, Oxford, United Kingdom
- +1 more
Nov 2, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial
Active, not recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +7 more
- Carboplatin
- +5 more
-
Jacksonville, Florida
- +11 more
Jan 12, 2023
Intracranial Germ Cell CNS Tumor, Childhood Trial in Beijing (radiation, drug, procedure)
Recruiting
- Intracranial Germ Cell CNS Tumor, Childhood
- Whole-ventricle irradiation
- +3 more
-
Beijing, ChinaBeijing Tiantan Hospital
Nov 7, 2021
DLBCL Unclassifiable, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial in Duarte,
Recruiting
- Diffuse Large B-Cell Lymphoma Unclassifiable
- +6 more
- Carboplatin
- +4 more
-
Duarte, California
- +1 more
Oct 1, 2021